palonosetron hydrochloride

DRUG13 trials

Sponsors

Heron Therapeutics, University of Washington, OHSU Knight Cancer Institute, Joseph Roscoe, M.D. Anderson Cancer Center

Conditions

Advanced CancerAnal CancerCarcinoma of the AppendixChemotherapy-Induced Nausea and VomitingChemotherapy-induced Nausea and VomitingColorectal CancerExtrahepatic Bile Duct CancerGallbladder Cancer

Phase 2

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

CompletedNCT00381862

OHSU Knight Cancer InstituteColorectal Cancer, Nausea and Vomiting

Start: 2006-06-30End: 2008-07-31Updated: 2017-06-12

Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

TerminatedNCT00895245

University of WashingtonNausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx +8

Start: 2009-02-28End: 2011-02-28Updated: 2017-05-18

Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer

TerminatedNCT00903396

Alliance for Clinical Trials in OncologyAnal Cancer, Carcinoma of the Appendix, Colorectal Cancer +9

Start: 2009-09-30End: 2013-05-31Updated: 2017-11-24

Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

CompletedNCT03040726

M.D. Anderson Cancer CenterMalignant Neoplasm, Nausea, Vomiting

Start: 2017-05-03End: 2022-02-14Updated: 2023-10-17

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

CompletedNCT03097588

OHSU Knight Cancer InstituteMalignant Neoplasm

Start: 2017-04-27End: 2020-03-20Updated: 2021-07-12

Protreat-Trial: Prophylactic Antiemetic Treatment of Opioid-induced Nausea and Vomiting (OINV) in Palliative Care

CompletedNCT05315999

Gerhild BeckerAdvanced Cancer, Nausea, Pain +1

Start: 2022-05-03End: 2024-12-18Updated: 2025-03-19

Phase 3

APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

CompletedNCT00343460

Heron TherapeuticsNausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific

Start: 2006-06-01End: 2009-02-01Updated: 2026-03-02

Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

CompletedNCT00475085

Joseph RoscoeNausea

Start: 2006-12-31Updated: 2015-11-10

Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer

CompletedNCT00553059

M.D. Anderson Cancer CenterChemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific

Start: 2008-05-31End: 2014-08-31Updated: 2020-10-09

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

CompletedNCT03578081

Alliance for Clinical Trials in OncologyMalignant Neoplasm

Start: 2018-11-20End: 2023-05-01Updated: 2025-04-06

Phase 4

Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting

CompletedNCT01481831

Shanghai Changzheng HospitalChemotherapy-Induced Nausea and Vomiting, Neoplasms

Start: 2011-07-31Updated: 2012-12-31

Unknown Phase

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

CompletedNCT00343863

University of WashingtonMale Breast Cancer, Nausea and Vomiting, Stage I Breast Cancer +2

Start: 2006-01-31End: 2010-12-31Updated: 2017-07-11

Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)

CompletedNCT01640340

Ohio State University Comprehensive Cancer CenterMalignant Neoplasm

Start: 2011-01-31End: 2011-08-31Updated: 2013-11-07

Related Papers

Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602)

The Oncologist2023-06-071 citations

Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).

Journal of Clinical Oncology2022-06-011 citations

Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial.

2021-01-012 citations

Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy

BMC Cancer2016-02-267 citations

Slow-Release Granisetron (APF530) Versus Palonosetron for Chemotherapy-Induced Nausea/Vomiting: Analysis by American Society of Clinical Oncology Emetogenicity Criteria

Future Oncology2015-08-2014 citations

A prospective, randomized, double-blind phase 3 trial of extended-release granisetron (APF530) versus palonosetron (PALO) for preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately (MEC) or highly (HEC) emetogenic chemotherapy: Does a reanalysis using newer ASCO emetogenicity criteria affect study conclusions?

Journal of Clinical Oncology2014-05-202 citations

Phase 3 trial of APF530 versus palonosetron (PALO) in preventing chemotherapy-induced nausea and vomiting (CINV): Efficacy in breast cancer patients (pts) receiving moderately (MEC) or highly (HEC) emetogenic chemotherapy.

Journal of Clinical Oncology2014-05-202 citations